Neoadjuvant Arimidex or Tamoxifen, alone or combined, for breast cancer (IMPACT): PgR-related reductions in proliferation marker Ki67. - Boeddinghaus,I.M.; Dowsett,M.; Smith,I.E. (Proc Am Soc Clin Oncol, 2000)